More on BMEA
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.69 |
|
|||
| Open | $0.69 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $0.69 | ||||
| Day Low | $0.69 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 4,593 | ||||
- Form 8-K Biomea Fusion, Inc. For: Oct 13
- Biomea Fusion (BMEA) Reiterated at Market Outperform by Citizens on BMF-650 Ph1 Data
- Biomea Fusion reports Phase 1 weight loss data for oral GLP-1 drug
- Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
- Biomea Fusion to release Phase I data for oral GLP-1 drug BMF-650
- Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
- Brookline Capital Markets Starts Biomea Fusion Inc. (BMEA) at Buy
- Biomea Fusion (BMEA) Reiterated at Market Outperform by Citizens - Time to 'Revisit This Story'
- Biomea Fusion cancels planned public offering citing market conditions
- Biomea Fusion Announces Termination of Proposed Public Offering of Securities
Entities mentioned with BMEA
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- JPMorgan | View Related Stories »
- 13G | View Related Stories »
- Show More...
